Float Short %

35.13

Margin Of Safety %

Put/Call OI Ratio

0.25

EPS Next Q Diff

0.04

EPS Last/This Y

0.08

EPS This/Next Y

0.41

Price

4.86

Target Price

Analyst Recom

2.25

Performance Q

-7.07

Relative Volume

0.82

Beta

0.95

Ticker: RXRX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	RXRX	4.76	0.22	0.22	486159
2025-12-10	RXRX	4.77	0.22	0.14	487793
2025-12-11	RXRX	4.57	0.22	0.30	488947
2025-12-12	RXRX	4.35	0.22	0.73	488919
2025-12-15	RXRX	4.18	0.24	0.23	475083
2025-12-16	RXRX	4.2	0.24	0.45	476062
2025-12-17	RXRX	4.69	0.25	0.25	474988
2025-12-18	RXRX	4.46	0.24	0.29	484419
2025-12-19	RXRX	4.29	0.24	0.47	485801
2025-12-22	RXRX	4.4	0.24	0.19	392143
2025-12-23	RXRX	4.35	0.24	0.40	406412
2025-12-26	RXRX	4.24	0.24	0.30	416497
2025-12-29	RXRX	4.13	0.25	0.32	407288
2025-12-30	RXRX	4.11	0.25	0.25	415344
2025-12-31	RXRX	4.08	0.26	0.23	420050
2026-01-02	RXRX	4.2	0.26	0.22	422482
2026-01-05	RXRX	4.36	0.26	0.16	415527
2026-01-06	RXRX	4.56	0.25	0.11	428173
2026-01-07	RXRX	4.84	0.25	0.13	438226
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	RXRX	4.77	34.7	-	-1.61
2025-12-10	RXRX	4.78	34.7	-	-1.61
2025-12-11	RXRX	4.57	34.7	-	-1.61
2025-12-12	RXRX	4.32	34.7	-	-1.61
2025-12-15	RXRX	4.20	34.7	-	-1.61
2025-12-16	RXRX	4.20	34.7	-	-1.61
2025-12-17	RXRX	4.68	34.7	-	-1.61
2025-12-18	RXRX	4.45	34.7	-	-1.61
2025-12-19	RXRX	4.27	39.0	-	-1.61
2025-12-22	RXRX	4.39	39.0	-	-1.61
2025-12-23	RXRX	4.34	39.0	-	-1.61
2025-12-26	RXRX	4.25	39.0	-	-1.61
2025-12-29	RXRX	4.12	39.0	-	-1.61
2025-12-30	RXRX	4.11	39.0	-	-1.61
2025-12-31	RXRX	4.09	39.0	-	-1.61
2026-01-02	RXRX	4.21	39.0	-	-1.61
2026-01-05	RXRX	4.36	39.0	-	-1.61
2026-01-06	RXRX	4.55	39.0	-	-1.61
2026-01-07	RXRX	4.86	39.0	-	-1.61
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	RXRX	-1.39	3.92	35.13
2025-12-10	RXRX	-1.39	3.92	36.63
2025-12-11	RXRX	-1.39	3.92	36.63
2025-12-12	RXRX	-1.39	3.92	35.19
2025-12-15	RXRX	-1.65	3.91	35.19
2025-12-16	RXRX	-1.65	3.91	35.19
2025-12-17	RXRX	-1.65	3.91	35.19
2025-12-18	RXRX	-1.65	3.91	35.19
2025-12-19	RXRX	-1.70	3.91	35.19
2025-12-22	RXRX	-1.70	3.91	35.19
2025-12-23	RXRX	-1.70	3.91	35.19
2025-12-26	RXRX	-1.70	3.91	35.62
2025-12-29	RXRX	-1.70	1.15	35.14
2025-12-30	RXRX	-1.96	1.15	35.14
2025-12-31	RXRX	-1.99	1.15	35.14
2026-01-02	RXRX	-1.99	1.15	35.14
2026-01-05	RXRX	-1.99	1.15	35.13
2026-01-06	RXRX	-1.99	1.15	35.13
2026-01-07	RXRX	-2.04	1.15	35.13
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.36

Avg. EPS Est. Current Quarter

-0.32

Avg. EPS Est. Next Quarter

-0.32

Insider Transactions

-2.04

Institutional Transactions

1.15

Beta

0.95

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.7

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

57.89

P/B

2.28

P/Free Cash Flow

EPS

-1.81

Average EPS Est. Cur. Y

-1.61

EPS Next Y. (Est.)

-1.2

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1637.81

Relative Volume

0.82

Return on Equity vs Sector %

-95.4

Return on Equity vs Industry %

-80.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Recursion Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 800

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

stock quote shares RXRX – Recursion Pharmaceuticals, Inc. Stock Price stock today

news today RXRX – Recursion Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RXRX – Recursion Pharmaceuticals, Inc. yahoo finance google finance

stock history RXRX – Recursion Pharmaceuticals, Inc. invest stock market

stock prices RXRX premarket after hours

ticker RXRX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RXRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y